Indirect action of tumor necrosis factor-alpha in liver injury during the CD8+ T cell response to an adeno-associated virus vector in mice
✍ Scribed by Matthew Giannandrea; Robert H. Pierce; Ian Nicholas Crispe
- Publisher
- John Wiley and Sons
- Year
- 2009
- Tongue
- English
- Weight
- 918 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
✦ Synopsis
CD8+ T cells can cause hepatocellular injury by two distinct mechanisms. In addition to their direct cytotoxic effect, there is also collateral liver injury, which occurs when cells are killed in an antigen-independent manner. Whereas immune effector cytokines interferon-gamma (IFNgamma) and tumor necrosis factor-alpha (TNFalpha) have both been implicated in various forms of hepatitis, their respective roles in direct and/or collateral liver damage remains unclear. In order to investigate these elements of liver injury, we developed a new experimental model of CD8+ T-cell-mediated hepatitis based on an adeno-associated virus-based gene therapy vector. This vector is used to deliver antigen to hepatocytes, and CD8+ T cells specific for the vector-encoded transgene are adoptively transferred to produce liver immunopathology. In this experimental model, CD8+ T-cell IFNgamma acts on Kupffer cells, inducing TNFalpha secretion and liver injury. Both IFNgamma and TNFalpha are important in this injury process, but TNFalpha acts as an autocrine amplifier of Kupffer cell function, rather than as a direct effector of hepatocellular damage.
Conclusions:
Tnfalpha indirectly promotes liver damage and is not a direct hepatotoxic agent. ifngamma also indirectly contributes to liver injury through kupffer cell activation while, in parallel, directly promoting hepatitis through induction of hepatocyte major histocompatability complex class i. in principle, it may be possible to ameliorate this immunopathologic indirect mechanism by developing therapies that target kupffer cells, without impairing cd8+ t-cell-mediated antiviral immunity. this would have great therapeutic potential in chronic viral hepatitis.